Skip to content

CELLULAR BIOMEDICINE GROUP, INC.: 10-K filed 2019-02-19

What CELLULAR BIOMEDICINE GROUP, INC. reported in its annual report filed 2019-02-19 (fiscal FY 2018): 44 published measures, 138 facts as tagged in accession 0001654954-19-001756.

This filing

Form
10-K (annual report)
Filed
2019-02-19
Fiscal period
fiscal FY 2018
Accession
0001654954-19-001756 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All CELLULAR BIOMEDICINE GROUP, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2018-12-3191,643,146USD
At 2017-12-3161,162,296USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2018-12-316,424,754USD
At 2017-12-313,859,770USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2018-12-3185,218,392USD
At 2017-12-3157,302,526USD
At 2016-12-3165,893,954USD
At 2015-12-3146,364,936USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2018-10-01 to 2018-12-31-8,519,229USD92
2018-01-01 to 2018-12-31-38,945,492USD365
2018-07-01 to 2018-09-30-12,743,764USD92
2018-04-01 to 2018-06-30-9,186,079USD91
2018-01-01 to 2018-03-31-8,496,423USD90
2017-10-01 to 2017-12-31-6,922,585USD92
2017-01-01 to 2017-12-31-25,490,310USD365
2017-07-01 to 2017-09-30-6,202,214USD92
2017-04-01 to 2017-06-30-6,203,518USD91
2017-01-01 to 2017-03-31-6,161,993USD90
2016-01-01 to 2016-12-31-28,208,376USD366

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2018-01-01 to 2018-12-31-25,112,999USD365
2017-01-01 to 2017-12-31-18,593,392USD365
2016-01-01 to 2016-12-31-15,867,735USD366

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2018-10-01 to 2018-12-3125,698USD92
2018-01-01 to 2018-12-31224,403USD365
2018-07-01 to 2018-09-3070,431USD92
2018-04-01 to 2018-06-3077,313USD91
2018-01-01 to 2018-03-3150,961USD90
2017-10-01 to 2017-12-3168,691USD92
2017-01-01 to 2017-12-31336,817USD365
2017-07-01 to 2017-09-30106,787USD92
2017-04-01 to 2017-06-3062,914USD91
2017-01-01 to 2017-03-3198,425USD90
2016-01-01 to 2016-12-31627,930USD366

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2018-01-01 to 2018-12-3163,114,302USD365
2017-01-01 to 2017-12-3110,826,482USD365
2016-01-01 to 2016-12-3143,285,554USD366

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2018-01-01 to 2018-12-31-6,609,225USD365
2017-01-01 to 2017-12-31-10,192,868USD365
2016-01-01 to 2016-12-31-2,733,407USD366

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2018-12-31-149,982,489USD
At 2017-12-31-111,036,997USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2018-01-01 to 2018-12-3117,741,104shares365
2017-01-01 to 2017-12-3114,345,604shares365
2016-01-01 to 2016-12-3113,507,408shares366

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2018-01-01 to 2018-12-3117,741,104shares365
2017-01-01 to 2017-12-3114,345,604shares365
2016-01-01 to 2016-12-3113,507,408shares366

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2018-01-01 to 2018-12-314,954USD365
2017-01-01 to 2017-12-312,450USD365
2016-01-01 to 2016-12-314,093USD366

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2018-12-3115,193,761USD
At 2017-12-3112,973,342USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2018-01-01 to 2018-12-314,826,745USD365
2017-01-01 to 2017-12-315,345,211USD365
2016-01-01 to 2016-12-315,452,417USD366

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2018-01-01 to 2018-12-31-40,505,745USD365
2017-01-01 to 2017-12-31-27,576,567USD365
2016-01-01 to 2016-12-31-28,415,334USD366

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2018-12-3154,607,711USD
At 2017-12-3123,794,846USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2018-12-316,166,936USD
At 2017-12-313,676,121USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2018-12-31422,752USD
At 2017-12-31225,287USD

Goodwill carrying amount

Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.

PeriodValueUnitDays
At 2018-12-317,678,789USD
At 2017-12-317,678,789USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2018-12-31787USD
At 2017-12-31202,887USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2018-01-01 to 2018-12-3140,730,148USD365
2017-01-01 to 2017-12-3127,913,384USD365
2016-01-01 to 2016-12-3129,043,264USD366

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2018-10-01 to 2018-12-314,113USD92
2018-07-01 to 2018-09-3032,948USD92
2018-04-01 to 2018-06-3022,920USD91
2018-01-01 to 2018-03-3128,661USD90
2017-10-01 to 2017-12-3137,266USD92
2017-01-01 to 2017-12-31174,599USD365
2017-07-01 to 2017-09-3051,493USD92
2017-04-01 to 2017-06-3024,817USD91
2017-01-01 to 2017-03-3161,023USD90

Cost of revenue

Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.

PeriodValueUnitDays
2018-01-01 to 2018-12-31135,761USD365
2017-01-01 to 2017-12-31162,218USD365
2016-01-01 to 2016-12-31860,417USD366

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2018-01-01 to 2018-12-3124,150,480USD365
2017-01-01 to 2017-12-3114,609,917USD365
2016-01-01 to 2016-12-3111,475,587USD366

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2018-12-3118,119,282shares
At 2017-12-3115,188,764shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2018-12-31250,604,618USD
At 2017-12-31172,691,339USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2018-12-31-1,469,192USD
At 2017-12-31-389,503USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2018-12-3122,056,966USD
At 2017-12-3116,815,450USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2018-12-316,863,205USD
At 2017-12-313,842,108USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2018-12-311,878,926USD
At 2017-12-311,097,327USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2018-12-311,692,135USD
At 2017-12-311,852,695USD

Net deferred tax assets

Deferred tax assets after the valuation allowance. Realization depends on future taxable income, so the balance is not a receivable from tax authorities.

PeriodValueUnitDays
At 2018-12-310USD
At 2017-12-310USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2018-01-01 to 2018-12-31-38,940,538USD365
2017-01-01 to 2017-12-31-25,487,860USD365
2016-01-01 to 2016-12-31-28,204,283USD366

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2018-01-01 to 2018-12-31-40,025,181USD365
2017-01-01 to 2017-12-31-24,763,121USD365
2016-01-01 to 2016-12-31-29,208,953USD366

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2018-01-01 to 2018-12-3113,220,757USD365
2017-01-01 to 2017-12-3112,780,483USD365
2016-01-01 to 2016-12-3111,670,506USD366

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2018-01-01 to 2018-12-313,360,517USD365
2017-01-01 to 2017-12-311,195,705USD365
2016-01-01 to 2016-12-31850,793USD366

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2018-01-01 to 2018-12-311,172,879USD365
2017-01-01 to 2017-12-311,955,086USD365
2016-01-01 to 2016-12-31132,108USD366

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2018-01-01 to 2018-12-311,565,207USD365
2017-01-01 to 2017-12-312,088,707USD365
2016-01-01 to 2016-12-31211,051USD366

Current income tax expense or benefit

Income tax expense or benefit for the period that is currently payable or refundable. It differs from cash taxes paid and from total tax expense.

PeriodValueUnitDays
2018-01-01 to 2018-12-31-4,954USD365
2017-01-01 to 2017-12-31-2,450USD365
2016-01-01 to 2016-12-31-4,093USD366

Deferred income tax expense or benefit

The deferred portion of income tax expense or benefit, arising from timing differences. It is not tax paid in the period.

PeriodValueUnitDays
2018-01-01 to 2018-12-310USD365
2017-01-01 to 2017-12-310USD365
2016-01-01 to 2016-12-310USD366

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2018-01-01 to 2018-12-3170,351,173USD365
2017-01-01 to 2017-12-3114,496,040USD365
2016-01-01 to 2016-12-3142,399,874USD366

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2018-01-01 to 2018-12-31-107,263USD365
2017-01-01 to 2017-12-31160,628USD365
2016-01-01 to 2016-12-31-537,155USD366

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2018-01-01 to 2018-12-310USD365
2017-01-01 to 2017-12-310USD365
2016-01-01 to 2016-12-31-514,734USD366

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2018-01-01 to 2018-12-31133,740USD365
2017-01-01 to 2017-12-31-814USD365
2016-01-01 to 2016-12-31-28,205USD366

Inspect the source

Entity
CELLULAR BIOMEDICINE GROUP, INC. / CIK 0001378624
Captured
SEC response SHA-256
b44d08863d62569e9fd817107b545bcd8036e0b5a0651202c09ca062cee0088a

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001378624.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))